Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069806
Filing Date
2025-05-13
Accepted
2025-05-13 07:38:20
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q achv-20250331.htm   iXBRL 10-Q 1924457
2 EX-31.1 achv-ex31_1.htm EX-31.1 11805
3 EX-31.2 achv-ex31_2.htm EX-31.2 11788
4 EX-32.1 achv-ex32_1.htm EX-32.1 7015
5 EX-32.2 achv-ex32_2.htm EX-32.2 6999
  Complete submission text file 0000950170-25-069806.txt   8146490

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20250331.xsd EX-101.SCH 1295971
67 EXTRACTED XBRL INSTANCE DOCUMENT achv-20250331_htm.xml XML 1338730
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 25937166
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)